Market Cap 5.89B
Revenue (ttm) 290.52M
Net Income (ttm) 89.16M
EPS (ttm) N/A
PE Ratio 30.43
Forward PE 32.85
Profit Margin 30.69%
Debt to Equity Ratio 0.00
Volume 199,400
Avg Vol 341,476
Day's Range N/A - N/A
Shares Out 29.00M
Stochastic %K 59%
Beta 0.65
Analysts Strong Sell
Price Target $223.89

Company Profile

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treati...

Industry: Biotechnology
Sector: Healthcare
Phone: 412 586 5830
Address:
2100 Wharton Street, Suite 701, Pittsburgh, United States
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:27 AM
$KRYS: The last close at $201.21 indicates a strong position within the recent trading range, having approached the 60D high of $212.98. The RSI at 69.18 suggests that the stock is nearing overbought territory, which could indicate a potential pullback. However, the rising MA30 at $191.71 and MA50 at $178.76 reflect a bullish trend in the short to medium term. Directional bias is cautiously bullish, given the proximity to the recent high and the upward momentum indicated by the moving averages. Suggested entry is around $200, with a stop loss set at $193 to manage risk. Target 1 is set at $210, just below the 60D high, while Target 2 is at $215, allowing for potential continuation if momentum persists. Monitor RSI for signs of reversal and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:33 AM
$KRYS: The market context indicates a strong upward trend, with the last close at $203.0, which is near the 60D high of $212.98. The RSI at 71.92 suggests that the stock is overbought, indicating a potential pullback or consolidation. The MA30 at $190.28 and MA50 at $176.67 show that the stock is trading well above its short-term moving averages, reinforcing the bullish trend but also highlighting the risk of a correction. Directional bias is cautiously bullish, but the overbought RSI signals a need for caution. Suggested entry could be around $200.00, with a stop loss set at $195.00 to manage risk. Target 1 is set at $210.00, just below the 60D high, while Target 2 is at $215.00, allowing for potential breakout gains. Monitor the RSI for signs of reversal, and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 12 at 7:43 PM
Stifel trimmed⬇️ $ABEO's PT to $19 from $20 and reiterated at a Buy rating. $KRYS Here's what Stifel had to say in its note:
0 · Reply
ZManicItalian
ZManicItalian Nov. 12 at 5:02 PM
$KRYS 🤑🤙
0 · Reply
MaverikIT
MaverikIT Nov. 12 at 3:09 PM
0 · Reply
Bio_Cash
Bio_Cash Nov. 12 at 2:05 PM
$ABEO Some conference takeaways: - no change to 2026 guidance - company prioritized a definitive of the patient release assay to a quick fix hence the delay, this is a one-off issue - of the 14 patients identified in Q2 ER, 12 have their ZFORM submitted meaning clinical approval of the treatment and patient approval - x2 identified patients vs Q2 ER - QTCs are direct driver for patients referral so far and therefore revenue, they are revenue gate keepers, no attrition is expected - profitability confirmed for H1 2026, no impact of launch delay on that - current leadtime for patients treatment time is 3 months but this is going to down as insurers have validated the treatment and therefore exceptions are less required - FDA label is from birth and above, insurers have sometime more restrictive authorizations but commercial is able to overturn that by showing benefits - revenue is recognized when the product is applied - Vast majority of patients validated have failed Vyjuvek of $KRYS
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:09 AM
$KRYS: The market context indicates a strong upward trend, with the last close at $203.0, which is near the 60D high of $212.98. The RSI at 71.92 suggests that the stock is overbought, indicating a potential pullback or consolidation. The MA30 at $190.28 and MA50 at $176.67 show that the stock is trading well above its short-term moving averages, reinforcing the bullish trend but also highlighting the risk of a correction. Directional bias is cautiously bullish, but the overbought RSI signals a need for caution. Suggested entry could be around $200.00, with a stop loss set at $195.00 to manage risk. Target 1 is set at $210.00, just below the 60D high, while Target 2 is at $215.00, allowing for potential breakout gains. Monitor the RSI for signs of reversal, and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 11 at 11:47 PM
0 · Reply
oreoPp
oreoPp Nov. 7 at 5:11 PM
$ABEO so it’s front running expecting not as good news next Wed morning. It’s following similar commercial ramp up by $KRYS 5/19/23 FDA approval 86-123 8/7/23 1st earnings call - no revenue but communicates interest 125-110 11/3/23 2nd earnings call - earnings with revenue. Stock ramped up to 124 higher expectation 11/4/23 3rd earnings not so hot. 124-98 Thru Feb 24 - ran up to 133 Came down to 112 before 2/26/24 earnings call - revenue 40% increase 112 - 157 $ABEO so far 4/30/24 FDA approval 5-7 8/14/24 1st earnings call - no revenue but communicates interest 6-7 11/7/25 3 days prior to 2nd earnings call, stock down 5-4 in past 5 trading days. 11/12/25 2nd earnings - lower expectation than $KRYS going in which had high expectation. Of course there are a lot of uncertainty but just pointing out it seems to be front running.
3 · Reply
Ortho91
Ortho91 Nov. 6 at 10:11 PM
$KRYS 💪🏻
0 · Reply
Latest News on KRYS
Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 11:46 AM EST - 10 days ago

Krystal Biotech, Inc. (KRYS) Q3 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:42 PM EDT - 3 months ago

Krystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript

May 6, 2025, 2:43 PM EDT - 6 months ago

Krystal Biotech, Inc. (KRYS) Q1 2025 Earnings Call Transcript


Krystal Biotech to Present at Upcoming Scientific Conferences

Apr 24, 2025, 8:00 AM EDT - 7 months ago

Krystal Biotech to Present at Upcoming Scientific Conferences


Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

Apr 7, 2025, 4:30 PM EDT - 7 months ago

Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer


Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 11:43 AM EST - 9 months ago

Krystal Biotech, Inc. (KRYS) Q4 2024 Earnings Call Transcript


Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy

Dec 27, 2024, 8:30 AM EST - 11 months ago

Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy


Krystal Biotech to Present at Upcoming Investor Conferences

Nov 27, 2024, 7:00 AM EST - 1 year ago

Krystal Biotech to Present at Upcoming Investor Conferences


Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript

May 6, 2024, 11:44 AM EDT - 1 year ago

Krystal Biotech, Inc. (KRYS) Q1 2024 Earnings Call Transcript


Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:47 AM EST - 1 year ago

Krystal Biotech, Inc. (KRYS) Q4 2023 Earnings Call Transcript


PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:27 AM
$KRYS: The last close at $201.21 indicates a strong position within the recent trading range, having approached the 60D high of $212.98. The RSI at 69.18 suggests that the stock is nearing overbought territory, which could indicate a potential pullback. However, the rising MA30 at $191.71 and MA50 at $178.76 reflect a bullish trend in the short to medium term. Directional bias is cautiously bullish, given the proximity to the recent high and the upward momentum indicated by the moving averages. Suggested entry is around $200, with a stop loss set at $193 to manage risk. Target 1 is set at $210, just below the 60D high, while Target 2 is at $215, allowing for potential continuation if momentum persists. Monitor RSI for signs of reversal and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:33 AM
$KRYS: The market context indicates a strong upward trend, with the last close at $203.0, which is near the 60D high of $212.98. The RSI at 71.92 suggests that the stock is overbought, indicating a potential pullback or consolidation. The MA30 at $190.28 and MA50 at $176.67 show that the stock is trading well above its short-term moving averages, reinforcing the bullish trend but also highlighting the risk of a correction. Directional bias is cautiously bullish, but the overbought RSI signals a need for caution. Suggested entry could be around $200.00, with a stop loss set at $195.00 to manage risk. Target 1 is set at $210.00, just below the 60D high, while Target 2 is at $215.00, allowing for potential breakout gains. Monitor the RSI for signs of reversal, and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 12 at 7:43 PM
Stifel trimmed⬇️ $ABEO's PT to $19 from $20 and reiterated at a Buy rating. $KRYS Here's what Stifel had to say in its note:
0 · Reply
ZManicItalian
ZManicItalian Nov. 12 at 5:02 PM
$KRYS 🤑🤙
0 · Reply
MaverikIT
MaverikIT Nov. 12 at 3:09 PM
0 · Reply
Bio_Cash
Bio_Cash Nov. 12 at 2:05 PM
$ABEO Some conference takeaways: - no change to 2026 guidance - company prioritized a definitive of the patient release assay to a quick fix hence the delay, this is a one-off issue - of the 14 patients identified in Q2 ER, 12 have their ZFORM submitted meaning clinical approval of the treatment and patient approval - x2 identified patients vs Q2 ER - QTCs are direct driver for patients referral so far and therefore revenue, they are revenue gate keepers, no attrition is expected - profitability confirmed for H1 2026, no impact of launch delay on that - current leadtime for patients treatment time is 3 months but this is going to down as insurers have validated the treatment and therefore exceptions are less required - FDA label is from birth and above, insurers have sometime more restrictive authorizations but commercial is able to overturn that by showing benefits - revenue is recognized when the product is applied - Vast majority of patients validated have failed Vyjuvek of $KRYS
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:09 AM
$KRYS: The market context indicates a strong upward trend, with the last close at $203.0, which is near the 60D high of $212.98. The RSI at 71.92 suggests that the stock is overbought, indicating a potential pullback or consolidation. The MA30 at $190.28 and MA50 at $176.67 show that the stock is trading well above its short-term moving averages, reinforcing the bullish trend but also highlighting the risk of a correction. Directional bias is cautiously bullish, but the overbought RSI signals a need for caution. Suggested entry could be around $200.00, with a stop loss set at $195.00 to manage risk. Target 1 is set at $210.00, just below the 60D high, while Target 2 is at $215.00, allowing for potential breakout gains. Monitor the RSI for signs of reversal, and adjust targets accordingly. https://privateprofiteers.com
0 · Reply
Mrstock2255
Mrstock2255 Nov. 11 at 11:47 PM
0 · Reply
oreoPp
oreoPp Nov. 7 at 5:11 PM
$ABEO so it’s front running expecting not as good news next Wed morning. It’s following similar commercial ramp up by $KRYS 5/19/23 FDA approval 86-123 8/7/23 1st earnings call - no revenue but communicates interest 125-110 11/3/23 2nd earnings call - earnings with revenue. Stock ramped up to 124 higher expectation 11/4/23 3rd earnings not so hot. 124-98 Thru Feb 24 - ran up to 133 Came down to 112 before 2/26/24 earnings call - revenue 40% increase 112 - 157 $ABEO so far 4/30/24 FDA approval 5-7 8/14/24 1st earnings call - no revenue but communicates interest 6-7 11/7/25 3 days prior to 2nd earnings call, stock down 5-4 in past 5 trading days. 11/12/25 2nd earnings - lower expectation than $KRYS going in which had high expectation. Of course there are a lot of uncertainty but just pointing out it seems to be front running.
3 · Reply
Ortho91
Ortho91 Nov. 6 at 10:11 PM
$KRYS 💪🏻
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 6:02 PM
Citigroup has adjusted their stance on Krystal Biotech ( $KRYS ), setting the rating to Neutral with a target price of 166 → 198.
0 · Reply
ZManicItalian
ZManicItalian Nov. 4 at 4:05 PM
$KRYS 🤑
0 · Reply
JarvisFlow
JarvisFlow Nov. 4 at 1:24 PM
Chardan Capital has updated their rating for Krystal Biotech ( $KRYS ) to Buy with a price target of 220.
0 · Reply
Ortho91
Ortho91 Oct. 31 at 8:45 PM
$KRYS 💪🏻💪🏻💪🏻
0 · Reply
cubie
cubie Oct. 31 at 8:01 PM
and spec bios $AXSM 120 or $150 $KRYS 170 or 220 $BNTX $90-$92S or $112S $TGTX $KPTI
0 · Reply
cubie
cubie Oct. 31 at 7:31 PM
$KRYS @judgeyoung2 whales both ways like $FRPT
0 · Reply
ZManicItalian
ZManicItalian Oct. 22 at 10:31 PM
$KRYS Japan commercial launch is a go 💪 https://www.linkedin.com/posts/krystal-biotech-inc_investor-news-krystal-biotech-japan-announced-activity-7386793424479477760-6gzK?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAAGBoSQBdIRLFO0gpLrUSXR2U8D-Tm6shcE&utm_campaign=copy_link
0 · Reply
Emma_Brownnn
Emma_Brownnn Oct. 21 at 11:54 AM
$KRYS another one in the same sector, with much more promising-looking chart. $BEAM had a monster 17.86% day.
0 · Reply
anachartanalyst
anachartanalyst Oct. 17 at 12:01 PM
$KRYS https://anachart.com/wp-content/uploads/ana_temp/1760702500_soc-img.jpg
0 · Reply
JarvisFlow
JarvisFlow Oct. 17 at 11:02 AM
B of A Securities updates rating for Krystal Biotech ( $KRYS ) to Buy, target set at 182 → 255.
0 · Reply
Quantumup
Quantumup Oct. 13 at 3:12 PM
H.C. Wainwright reiterated $ABEO Buy/$20 $KRYS HCW said: Last week, Abeona Therapeutics announced the activation of Children's Hospital Colorado as the newest qualified treatment center (QTC) for Abeona's marketed product ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. This first-of-its-kind therapy is FDA-approved to treat wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Children's Colorado in Aurora, CO—one of the pioneering institutions that provide advanced levels of care for people with epidermolysis bullosa (EB) and a member of the EB Clinical Research Consortium—has completed the applicable QTC start-up activities, enabling the initiation of patient identification for scheduling of ZEVASKYN treatment. In our view, the establishment of another QTC demonstrates Abeona's continued execution with respect to the rollout of ZEVASKYN. We reiterate our Buy rating and 12-month price target of $20.
0 · Reply
Ortho91
Ortho91 Oct. 11 at 2:03 AM
$KRYS shorts are playing with fire now.
0 · Reply